Skip to main content

Advertisement

SpringerLink
Log in

Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We determined, in our surrounding environment, the proportion of patients being treated with infliximab who required a therapeutic scheme escalation (an infliximab dose increase surpassing the level of 3 mg/kg every 8 weeks and/or a decrease on the current between infusions’ interval). This was a study of the retrospective analysis of data from the 41 rheumatoid arthritis (RA) patients receiving an infliximab therapy at the Albert Einstein Israelita Hospital, from January 2001 up to December 2005. A questionnaire was applied to these patients, assessing their clinical and laboratory data, adverse events, and individual information regarding the infliximab administration. Therapeutic dose information was available in 68% (28/41) of the RA patients, with 46% of these (13/28) receiving a dose increase, and 30% (8/27) experiencing a shortening of the between infusions’ interval. The average final infliximab dose (4.21 mg/kg) was significantly greater than their average initial dose (3.29 mg/kg). The average time intervals between the initial and final infusions, though shortened, were not significantly different. A proportion of 73% (30/41) of these patients demonstrated improvement in at least one of the assessed clinical parameters, and 50% of these patients (15/30) experienced a dose increase, while 20% (6/30) experienced shortening of the between treatments’ interval. A total of 20% (8/41) of the original patients experienced adverse events. Although infliximab is effective in the control of RA, dose adjustment and/or shortening of the between treatments’ interval is frequently required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol Immunol 30(16):1443–1453

    Article  PubMed  CAS  Google Scholar 

  2. Lyseng-Williamson KA, Foster RH (2004) Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 22(2):107–132

    Article  PubMed  Google Scholar 

  3. St Clair EW, Wagner CL, Fasanmade AA et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451–1459

    Article  PubMed  CAS  Google Scholar 

  4. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Cohen MD (2004) Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 10(6):538–542

    PubMed  Google Scholar 

  5. Stern R, Wolfe F (2004) Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31(8):1538–1545

    PubMed  CAS  Google Scholar 

  6. Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT (2004) Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 63(2):144–148

    Article  PubMed  CAS  Google Scholar 

  7. van Vollenhoven RF, Brannemark S, Klareskog L (2004) Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 63(4):426–430

    Article  PubMed  Google Scholar 

  8. Ollendorf DA, Massarotti E, Birbara C, Burgess SM (2005) Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 11(5):383–393

    PubMed  Google Scholar 

  9. Agarwal SK, Maier AL, Chibnik LB et al (2005) Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 53(6):872–878

    Article  PubMed  CAS  Google Scholar 

  10. Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J (2007) Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 46(3):529–532

    Article  CAS  Google Scholar 

  11. Flendrie M, Creemers MC, van Riel PL (2007) Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 46(1):146–149

    Article  CAS  Google Scholar 

  12. Shergy WJ, Isern RA, Cooley DA et al (2002) Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 29(4):667–677

    PubMed  CAS  Google Scholar 

  13. Lequerre T, Vittecoq O, Klemmer N et al (2006) Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33(7):1307–1314

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE), Av. Albert Einstein, 627 (sala 1209), São Paulo, 05651-901, Brazil

    Morton Scheinberg

  2. Hospital Israelita Albert Einstein, São Paulo, Brazil

    Morton Scheinberg, José Goldenberg, Daniel P. Feldman & João Luiz Nóbrega

Authors
  1. Morton Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Goldenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel P. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. João Luiz Nóbrega
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morton Scheinberg.

Additional information

This work received a grant in aid from Bristol Myers Squibb

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheinberg, M., Goldenberg, J., Feldman, D.P. et al. Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil. Clin Rheumatol 27, 1049–1052 (2008). https://doi.org/10.1007/s10067-008-0908-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-008-0908-y

Keywords

Search

Navigation